AGLE
- Aeglea BioTherapeutics, Inc.
()
Overview
Company Summary
Aeglea BioTherapeutics, Inc. (AGLE) is a biotechnology company focused on developing novel enzyme-based therapies to treat rare genetic diseases and cancer. The company uses its proprietary technology platform to engineer enzymes that can degrade specific amino acids in the body.
AGLE's primary focus is on developing therapeutic candidates that target important biological pathways where its enzyme-based treatments could have a significant impact. The company's lead product candidate, pegzilarginase (also known as AEB1102), is being evaluated for the treatment of Arginase 1 Deficiency (ARG1-D), a rare genetic disorder that causes the accumulation of toxic levels of arginine in the blood.
By administering pegzilarginase, AGLE aims to reduce arginine levels in patients, preventing the toxic buildup and addressing the debilitating symptoms associated with ARG1-D. If successful, this therapy could greatly improve the quality of life for individuals affected by this disorder.
Additionally, Aeglea BioTherapeutics is exploring other potential therapeutic applications for their enzyme-based approach. The company's platform technology enables the development of enzyme therapies for diseases where certain amino acids play a crucial role in disease progression. These include cancers that depend on certain amino acids for growth and survival.
AGLE's long-term strategy is to continue expanding its pipeline by applying its proprietary enzyme engineering technology to develop therapies for rare genetic diseases and cancer. Through rigorous research, clinical trials, and partnerships, the company aims to bring innovative treatments to patients in need.